Parkinson’s Disease Therapeutics: Emphasis on Nanotechnological Advances

Description

Parkinson’s Disease Therapeutics: Emphasis on Nanotechnological Advances presents the latest information on the second most common neurodegenerative disorder in the elderly. Despite remarkable progress in various PD therapeutics, such as microRNAs and brain drug delivery systems, a few limitations impede their success. This book sheds light on the pros and cons of recently developed novel therapeutics. Very few books have highlighted the protective efficacy of natural products, antioxidants, and biomaterial design for other diseases. PARKINSON’S DISEASE THERAPEUTICS Copyright Dedication Biography Acknowledgments 1 - Introduction: Parkinson's disease pathology and therapeutics 1. Introduction 1.1 Pathology 2. Micro-ribonucleic acid 3. Drugs 4. Viral vectors 4.1 Nanotechnology 4.2 Multifarious nanoparticles and surface functionalization 4.3 Nanoparticles in drug and gene delivery 4.4 High-density lipoprotein nanoparticles 4.5 Liposomes 4.6 Demerits of nanotechnology 5. Conclusions and future perspectives References Further reading 2 - Biomaterials: a boon or a bane in the treatment of Parkinson's disease 1. Introduction 2. Oxidative stress 3. Nanoparticles 4. Neurturin 5. Delivery systems for natural compounds 6. Diagnosis 7. Silver nanoparticles 8. Immunotherapy 9. Shortcomings of nanotechnology 10. Conclusions and future perspectives References Further reading 3 - Blood-brain barrier targeted nanoparticles 1. Introduction 1.1 Physiology 2. Blood-brain barrier impairment 2.1 Nanoparticles 2.2 Cerium oxide nanoparticles 3. Blood-brain barrier spanning of nanoparticles 4. Parkinson's disease 5. Nanoparticles for Parkinson's disease 6. Gold nanoparticles 7. Quercetin nanoparticles 8. Conclusions and future perspectives References Further reading 4 - Natural compounds in the treatment of Parkinson's disease 1. Introduction 1.1 Oxidative stress 2. Plant-derived compounds 2.1 Chinese herbs 2.2 Flavonoids 2.3 Mitochondria 2.3.1 Epigallocatechin gallate 2.4 Silibinin 2.5 Naringenin 2.6 Baicalein 2.7 Polyphenols 2.8 Polyphenolic flavonoids 2.8.1 Anthocyanins 3. Amelioration of antioxidant enzymes 3.1 Glutathione 3.2 Metal chelation 4. Conclusions and future perspectives References 5 - Curcumin: a promising therapeutic in Parkinson's disease treatment 1. Introduction 2. Antioxidant activity 3. 6-Hydroxydopamine and MPTP PD models 4. α-Synuclein targeting 5. Curcumin derivatives 6. Bioavailability 7. Heat shock proteins 8. Antiapoptosis 9. Metal chelation 10. Delivery systems for curcumin 11. Conclusions and future perspectives References 6 - Redox nanoparticles: the corner stones in the development of Parkinson's disease therapeutics 1. Introduction 2. Parkinson's disease diagnosis 3. Coenzyme Q10 3.1 Nanotechnology 3.2 Coenzyme Q10 delivery system 3.3 Nanozyme 3.4 Dopamine nanoparticles 3.4.1 Redox-active nanoparticles 3.4.2 Cerium oxide nanoparticles 4. Conclusions and future perspectives References 7 - Liposomal maneuvers against Parkinson's disease 1. Introduction 1.1 Parkinson's disease 2. Blood-Brain Barrier 3. Liposomes 4. Surface functionalization in brain targeting 4.1 Liposomes in Parkinson's disease 4.2 Liposomes in dopamine delivery 4.3 Liposomes for natural compounds 4.3.1 Curcumin 4.4 Fibroblast Growth Factor 4.5 Solid lipid nanoparticles 5. Demerits of liposomes 6. Conclusions and future perspectives References Further reading 8 - Nasal delivery nanoparticles: An insight into novel Parkinson's disease therapeutics 1. Introduction 2. Nasal delivery 3. Challenges in nasal delivery 3.1 Nanotechnology 3.2 Liposomes 3.3 Surface functionalization 3.4 Chitosan Nanoparticles 3.5 Nanostructured lipid carriers 3.6 Peptide-based carriers 3.7 Polysaccharide-based Nanoparticles 4. Demerits of nose to brain delivery 5. Conclusions and future perspectives References Further reading 9 - α-Synuclein-targeted nanoparticles 1. Introduction 1.1 α-Synuclein 2. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment 3. Fibrillation 4. Early diagnosis 4.1 Therapy 4.1.1 Nanotechnology 4.1.1.1 Nanotechnology for Parkinson's disease diagnosis 4.1.2 Nanotechnology for Parkinson's disease therapy 4.1.3 Dendrimers 4.1.4 Curcumin and curcumin-loaded nanoparticles 4.1.5 Nanoparticles targeted at α-synuclein fibrillation 5. Conclusions and future perspectives References Further reading 10 - Pros and cons of Parkinson's disease therapeutics 1. Introduction 2. α-Synuclein 3. Caenorhabditis elegans: a potential animal model for Parkinson's disease 4. Blood-brain barrier 5. Stem cell therapy 6. Influence of gut microbiota on neurodegenerative diseases 6.1 Nanotechnology 6.2 Lactoferrin-functionalized nanoparticles 6.3 Nanotechnology for stem cell therapy 6.4 Rasagiline-loaded chitosan nanoparticles 6.5 Dopamine transporting nanoparticles 7. Conclusions and future perspectives References Index A B C D E F G H I K L M N O P Q R S T U V